NCT01990534 2021-04-09A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin LymphomaTakedaPhase 4 Completed60 enrolled 21 charts
NCT01421667 2016-11-28A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin LymphomaSeagen Inc.Phase 2 Completed176 enrolled 30 charts
NCT00051597 2011-10-12A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic MalignanciesSeagen Inc.Phase 1/2 Completed70 enrolled